Search Bar & Filters
Found 4 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating how well CagriSema and cagrilintide help children and adolescents aged 8 to under 18 years with excess body weight lose weight. This phase 3 study compares these new study drugs with semaglutide, a medication already prescribed for adolescents and adults, and a placebo. The trial aims to understand the efficacy, safety, and pharmacokinetics of these treatments for weight management in young people with overweight or obesity. Participants are randomly assigned to receive once weekly subcutaneous doses of either CagriSema a combination of cagrilintide and semaglutide, cagrilintide alone, semaglutide alone, or placebo in a dose escalation regimen for up to 16 weeks, followed by maintenance for a total of 52 weeks in the main study. Those who participate in the extension study will continue receiving either CagriSema or cagrilintide for up to an additional 156 weeks. Participants receiving semaglutide do not enter the extension phase. The placebo group will receive a matched placebo during the main phase and then continue on the CagriSema regimen during the extension. During the study, participants will be closely monitored through various assessments including body mass index BMI changes, body weight, fat and muscle measurements by imaging methods like MRI and DXA scans, blood tests for metabolic markers, and quality of life questionnaires. These evaluations occur at baseline, week 68, and for some measures, week 224. Safety is monitored by tracking adverse events and other health indicators. The total participation time is about 1.5 years in the main study and up to nearly 5 years if including the extension phase.
Actively Recruiting
Researchers are evaluating Debio 4126, a 12-week extended-release formulation of octreotide, for treating adults with acromegaly who have previously been treated with somatostatin analogs. The main goal is to assess how well Debio 4126 maintains insulin-like growth factor 1 IGF-1 levels at or below the upper limit of normal ULN during a 36-week double-blind period compared to a placebo. This Phase 3 trial involves participants whose acromegaly is stable on prior treatment and meets specific health requirements. During the first 36 weeks Period 1, participants receive either Debio 4126 or a placebo via intramuscular injection every 12 weeks, totaling three injections. Participants whose IGF-1 levels remain controlled may continue into Period 2, where all receive open-label Debio 4126 injections every 12 weeks for an additional 24 to 60 weeks. Rescue medication is available if acromegaly is not well controlled, and dosing continues based on IGF-1 levels and response. Throughout the study, participants undergo regular assessments including IGF-1 monitoring, safety evaluations, and examination of injection site tolerability. Researchers measure the percentage of participants maintaining IGF-1 at or below ULN, changes in growth hormone levels, treatment-emergent adverse events, and plasma concentrations of Debio 4126 over up to 108 weeks. The study includes safety monitoring and allows for long-term follow-up to evaluate treatment effects.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of NNC0487-0111 for treating adults with excess body weight and type 2 diabetes. The study compares four different doses of NNC0487-0111 with a placebo, which contains no active medicine. Participants receive these treatments as weekly injections under the skin, and their group assignment is decided randomly. Participants are assigned to one of five groups four groups receive different dose levels of NNC0487-0111, and one group receives a placebo. All participants also follow a reduced-calorie diet and increase their physical activity. The injections are administered once weekly using a pre-filled pen injector to the thigh, abdomen, or upper arm. Treatment continues for 84 weeks, with ongoing monitoring. Throughout the study, participants will have their body weight, waist circumference, blood sugar control HbA1c, blood pressure, cholesterol levels, and quality of life assessed at the start and at week 84. Safety is monitored by tracking adverse events and episodes of low blood sugar up to week 88. The study lasts for about 84 weeks of treatment plus safety follow-up, and participants may undergo laboratory tests and physical exams during this time.
Actively Recruiting
Researchers are evaluating the combination of baxdrostat and dapagliflozin compared with dapagliflozin alone in adults aged 40 years and older who have type 2 diabetes, established cardiovascular disease, a history of hypertension with elevated systolic blood pressure, and at least one additional risk factor for heart failure. This phase III trial aims to assess whether adding baxdrostat can reduce the risk of heart failure events or cardiovascular death. Participants will be randomly assigned to receive either baxdrostat with dapagliflozin or placebo with dapagliflozin. Those not currently on SGLT2 inhibitors or treated for less than 4 weeks will enter a run-in period taking dapagliflozin alone for 4 to 6 weeks before randomization. Doses of baxdrostat may be increased if criteria are met. Study visits occur at 2, 4, 8, 16, and 34 weeks after randomization and then approximately every 4 months until the study ends when enough cardiovascular events have occurred. During the study, participants will have regular assessments including blood pressure and laboratory tests to monitor safety and efficacy. If participants stop the blinded study treatment early, they may continue open-label dapagliflozin. The main outcome is to see if the combination reduces heart failure events or cardiovascular death compared to dapagliflozin alone, with follow-up lasting up to 38 months. Data collection and scheduled visits will continue throughout the study period.